Jointown Pharmaceutical Group Co (600998.SS) Stock Price

Jointown Pharmaceutical Group Co Price

🇨🇳SSE·CLOSED
4.72CNY
Market closed
Today +/-
Today %

Jointown Pharmaceutical Group Co (600998.SS) Stock | ISIN CNE100000W45. The current Jointown Pharmaceutical Group Co stock price is 4.72 CNY (2026). Revenue is 173.82 B CNY. Net income is 2.69 B CNY. The P/E ratio is 8.81. Market capitalization is 23.67 B CNY. Jointown Pharmaceutical Group Co operates in the Health sector.

Over the last 17 years Jointown Pharmaceutical Group Co grew revenue by 15.5% annually, reaching 151.81 B CNY. Earnings per share have grown at 2.3% per year over the last 17 years. For Jointown Pharmaceutical Group Co, the net margin of 1.7% is down versus 2.7% a few years ago. At today's price the dividend yield works out to roughly 4.11%. The payout ratio is around 32% of earnings. The dividend has grown at 5.2% per year over the past 13 years.

Jointown Pharmaceutical Group Co stock price

Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Jointown Pharmaceutical Group Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Jointown Pharmaceutical Group Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Jointown Pharmaceutical Group Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Jointown Pharmaceutical Group Co Stock Price History
DateJointown Pharmaceutical Group Co Price
Access this data via the Eulerpool API
Get Free API Key

Jointown Pharmaceutical Group Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2007
13.05 B CNY
248 M CNY
160 M CNY
Jan 1, 2008
16.29 B CNY
330 M CNY
203 M CNY
Jan 1, 2009
18.96 B CNY
425 M CNY
298 M CNY
Jan 1, 2010
21.19 B CNY
570 M CNY
360 M CNY
Jan 1, 2011
24.84 B CNY
525 M CNY
374 M CNY
Jan 1, 2012
29.51 B CNY
681 M CNY
413 M CNY
Jan 1, 2013
33.44 B CNY
805 M CNY
478 M CNY
Jan 1, 2014
41.07 B CNY
980 M CNY
561 M CNY
Jan 1, 2015
49.59 B CNY
1.3 B CNY
695 M CNY
Jan 1, 2016
61.56 B CNY
1.67 B CNY
820 M CNY
Jan 1, 2017
73.94 B CNY
2.1 B CNY
1.34 B CNY
Jan 1, 2018
87.14 B CNY
2.56 B CNY
1.12 B CNY
Jan 1, 2019
99.5 B CNY
3.31 B CNY
1.56 B CNY
Jan 1, 2020
110.86 B CNY
3.78 B CNY
2.96 B CNY
Jan 1, 2021
122.41 B CNY
3.19 B CNY
2.44 B CNY

Jointown Pharmaceutical Group Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 23, 2026, 11:54 AM
 
REVENUE (B CNY)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B CNY)
NET INCOME (B CNY)
NET INCOME GROWTH (%)
DIV. (CNY)
DIV. GROWTH (%)
SHARES (B)
DOCUMENTS
202020212022202320242025e2026e2027e
110.86122.41140.42150.14151.81164.59173.82182.02
11.4210.4214.726.921.118.425.614.71
8.948.017.768.027.767.166.786.47
9.919.810.912.0411.7811.7811.7811.78
2.962.442.072.172.512.672.692.88
89.45-17.79-14.944.9215.326.620.497.15
-0.50.30.340.190.20.160.18
––-4013.33-44.125.26-2012.5
1.915.165.045.15.015.015.015.01
––––––––
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Jointown Pharmaceutical Group Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Jointown Pharmaceutical Group Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Jointown Pharmaceutical Group Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Jointown Pharmaceutical Group Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Jointown Pharmaceutical Group Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Jointown Pharmaceutical Group Co stock margins

The Jointown Pharmaceutical Group Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Jointown Pharmaceutical Group Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Jointown Pharmaceutical Group Co.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2007
4.95 %
1.9 %
1.23 %
Jan 1, 2008
5.51 %
2.03 %
1.25 %
Jan 1, 2009
5.93 %
2.24 %
1.57 %
Jan 1, 2010
6.43 %
2.69 %
1.7 %
Jan 1, 2011
5.89 %
2.11 %
1.51 %
Jan 1, 2012
6.34 %
2.31 %
1.4 %
Jan 1, 2013
6.65 %
2.41 %
1.43 %
Jan 1, 2014
7.08 %
2.39 %
1.37 %
Jan 1, 2015
7.54 %
2.61 %
1.4 %
Jan 1, 2016
7.83 %
2.71 %
1.33 %
Jan 1, 2017
8.43 %
2.84 %
1.81 %
Jan 1, 2018
8.62 %
2.94 %
1.29 %
Jan 1, 2019
8.73 %
3.32 %
1.57 %
Jan 1, 2020
8.94 %
3.41 %
2.67 %
Jan 1, 2021
8.01 %
2.61 %
1.99 %

Jointown Pharmaceutical Group Co Stock Revenue, EBIT, Earnings per Share

The Jointown Pharmaceutical Group Co earnings per share therefore indicates how much revenue Jointown Pharmaceutical Group Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2007
27.53 CNY
0.52 CNY
0.34 CNY
Jan 1, 2008
13.91 CNY
0.28 CNY
0.17 CNY
Jan 1, 2009
15.85 CNY
0.36 CNY
0.25 CNY
Jan 1, 2010
16.35 CNY
0.44 CNY
0.28 CNY
Jan 1, 2011
17.48 CNY
0.37 CNY
0.26 CNY
Jan 1, 2012
20.77 CNY
0.48 CNY
0.29 CNY
Jan 1, 2013
23.53 CNY
0.57 CNY
0.34 CNY
Jan 1, 2014
26.36 CNY
0.63 CNY
0.36 CNY
Jan 1, 2015
30.11 CNY
0.79 CNY
0.42 CNY
Jan 1, 2016
40.55 CNY
1.1 CNY
0.54 CNY
Jan 1, 2017
39.35 CNY
1.12 CNY
0.71 CNY
Jan 1, 2018
46.4 CNY
1.36 CNY
0.6 CNY
Jan 1, 2019
58.53 CNY
1.95 CNY
0.92 CNY
Jan 1, 2020
58.01 CNY
1.98 CNY
1.55 CNY
Jan 1, 2021
23.71 CNY
0.62 CNY
0.47 CNY

Jointown Pharmaceutical Group Co business model & stock analysis

Jointown Pharmaceutical Group Co Ltd is a Chinese company specializing in the production and distribution of pharmaceuticals. The company was founded in 1999 in Wuhan and has since become a significant player in the pharmaceutical industry. The company's business model is based on the production and sale of generic drugs, which are cheaper alternatives to existing medications. This makes them more affordable for many people. Jointown Pharmaceuticals operates in various areas, with one of the main areas being the production of cancer drugs. The company manufactures a variety of cancer medications and is one of the leading manufacturers in China in this field. Jointown Pharmaceuticals is also active in other areas of medicine, such as producing medications for diabetes, infectious diseases, and cardiovascular diseases. The company offers a wide range of products, including generics, patented medications, medical devices, diagnostics, dietary supplements, and cosmetic products. Jointown Pharmaceuticals emphasizes close collaboration with scientific institutions and partnerships with foreign partners in order to drive the development of new products and expand internationally. Jointown is also active in Germany through its subsidiary, Jointown Europe GmbH. The company's history is marked by steady growth. Jointown Pharmaceuticals has become one of the leading pharmaceutical companies in China within a few years and has gained international recognition. In 2013, the company successfully went public, generating additional financial resources. In addition to its pharmaceutical business, Jointown Pharmaceuticals is also involved in social projects. The company contributes to the fight against poverty and diseases in China and prioritizes environmental protection and sustainability. Overall, Jointown Pharmaceuticals is an innovative and successful company in the pharmaceutical industry. Its focus on the production of generics contributes significantly to providing affordable medications to the population. The wide range of products and the close collaboration with international partners demonstrate a modern and globally oriented corporate culture.

Jointown Pharmaceutical Group Co SWOT Analysis

Strengths

Jointown Pharmaceutical Group Co Ltd possesses several key strengths that contribute to its success in the market. These strengths include:

  • Strong market presence and brand reputation
  • Extensive product portfolio, catering to diverse healthcare needs
  • Efficient supply chain management, ensuring timely delivery
  • Robust research and development capabilities
  • Strong financial position, allowing for investment and growth opportunities

Despite its strengths, Jointown Pharmaceutical Group Co Ltd also faces certain weaknesses that pose challenges to its overall performance:

  • Limited international presence and dependence on the domestic market
  • Relatively smaller-scale operations compared to some global competitors
  • Higher reliance on third-party suppliers for raw materials
  • Potential vulnerability to changes in government regulations and policies

Jointown Pharmaceutical Group Co Ltd has several potential opportunities that can be leveraged to further enhance its market position:

  • Expanding into international markets, tapping into growing healthcare sectors
  • Investing in advanced technologies to improve manufacturing and distribution processes
  • Collaborating with research institutions to develop innovative healthcare solutions
  • Acquiring or partnering with complementary businesses to diversify product offerings
  • Catering to the rising demand for telehealth and online healthcare services

Jointown Pharmaceutical Group Co Ltd faces several threats that may impact its performance and market position:

  • Intense competition from both domestic and international pharmaceutical companies
  • Increase in counterfeit drugs and strict regulations against their distribution
  • Potential disruptions in the supply chain, such as natural disasters or pandemics
  • Changing consumer preferences and shift towards generic drugs
  • Evolving healthcare policies and pricing pressures

Weaknesses

Despite its strengths, Jointown Pharmaceutical Group Co Ltd also faces certain weaknesses that pose challenges to its overall performance:

  • Limited international presence and dependence on the domestic market
  • Relatively smaller-scale operations compared to some global competitors
  • Higher reliance on third-party suppliers for raw materials
  • Potential vulnerability to changes in government regulations and policies

Jointown Pharmaceutical Group Co Ltd has several potential opportunities that can be leveraged to further enhance its market position:

  • Expanding into international markets, tapping into growing healthcare sectors
  • Investing in advanced technologies to improve manufacturing and distribution processes
  • Collaborating with research institutions to develop innovative healthcare solutions
  • Acquiring or partnering with complementary businesses to diversify product offerings
  • Catering to the rising demand for telehealth and online healthcare services

Jointown Pharmaceutical Group Co Ltd faces several threats that may impact its performance and market position:

  • Intense competition from both domestic and international pharmaceutical companies
  • Increase in counterfeit drugs and strict regulations against their distribution
  • Potential disruptions in the supply chain, such as natural disasters or pandemics
  • Changing consumer preferences and shift towards generic drugs
  • Evolving healthcare policies and pricing pressures

Opportunities

Jointown Pharmaceutical Group Co Ltd has several potential opportunities that can be leveraged to further enhance its market position:

  • Expanding into international markets, tapping into growing healthcare sectors
  • Investing in advanced technologies to improve manufacturing and distribution processes
  • Collaborating with research institutions to develop innovative healthcare solutions
  • Acquiring or partnering with complementary businesses to diversify product offerings
  • Catering to the rising demand for telehealth and online healthcare services

Jointown Pharmaceutical Group Co Ltd faces several threats that may impact its performance and market position:

  • Intense competition from both domestic and international pharmaceutical companies
  • Increase in counterfeit drugs and strict regulations against their distribution
  • Potential disruptions in the supply chain, such as natural disasters or pandemics
  • Changing consumer preferences and shift towards generic drugs
  • Evolving healthcare policies and pricing pressures

Threats

Jointown Pharmaceutical Group Co Ltd faces several threats that may impact its performance and market position:

  • Intense competition from both domestic and international pharmaceutical companies
  • Increase in counterfeit drugs and strict regulations against their distribution
  • Potential disruptions in the supply chain, such as natural disasters or pandemics
  • Changing consumer preferences and shift towards generic drugs
  • Evolving healthcare policies and pricing pressures

Jointown Pharmaceutical Group Co Eulerpool Fair Value

Jointown Pharmaceutical Group Co historical P/E ratio, EBIT multiple, and P/S ratio

Jointown Pharmaceutical Group Co annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Jointown Pharmaceutical Group Co shares outstanding

The number of shares was Jointown Pharmaceutical Group Co in 2025 — This indicates how many shares 5.015 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2007
474 M base_Shares
Jan 1, 2008
1.17 B base_Shares
Jan 1, 2009
1.2 B base_Shares
Jan 1, 2010
1.3 B base_Shares
Jan 1, 2011
1.42 B base_Shares
Jan 1, 2012
1.42 B base_Shares
Jan 1, 2013
1.42 B base_Shares
Jan 1, 2014
1.56 B base_Shares
Jan 1, 2015
1.65 B base_Shares
Jan 1, 2016
1.52 B base_Shares
Jan 1, 2017
1.88 B base_Shares
Jan 1, 2018
1.88 B base_Shares
Jan 1, 2019
1.7 B base_Shares
Jan 1, 2020
1.91 B base_Shares
Jan 1, 2021
5.16 B base_Shares

Jointown Pharmaceutical Group Co Dividend History

10 years of dividend payments

YearAnnual DividendYoY ChangePayments
20250.2CNY↑ 3.2%1×
Jun 17, 20250.2CNY↑ 3.2%1/1
20240.19CNY↓ 42.2%1×
20230.34CNY↑ 11.9%1×
20220.3CNY↓ 40.0%1×
20210.5CNY↑ 400.0%1×
20190.1CNY 0.0%1×
20180.1CNY↓ 23.1%1×
20160.13CNY↑ 30.0%1×
20140.1CNY 0.0%1×
20110.1CNY—1×

Jointown Pharmaceutical Group Co dividend history and estimates

In 2025, Jointown Pharmaceutical Group Co paid a dividend amounting to 0.2 CNY. Dividend means that Jointown Pharmaceutical Group Co distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Invalid Date
0.1 CNY
-0.03 CNY
Invalid Date
0.1 CNY
-0.03 CNY
Invalid Date
0.13 CNY
-0.03 CNY
Jan 1, 2018
0.1 CNY
0 CNY
Jan 1, 2019
0.1 CNY
0 CNY
Jan 1, 2021
0.5 CNY
0 CNY
Jan 1, 2022
0.3 CNY
0 CNY
Jan 1, 2023
0.34 CNY
0 CNY
Jan 1, 2024
0.19 CNY
0 CNY
Jan 1, 2025
0.2 CNY
0 CNY
Invalid Date
0 CNY
0.16 CNY
Invalid Date
0 CNY
0.18 CNY

Jointown Pharmaceutical Group Co dividend payout ratio

In 2025, Jointown Pharmaceutical Group Co had a payout ratio of 29.76%. The payout ratio indicates the percentage of the company's profits that Jointown Pharmaceutical Group Co distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2007
23.51 %
Jan 1, 2008
23.51 %
Jan 1, 2009
23.51 %
Jan 1, 2010
23.51 %
Jan 1, 2011
14.31 %
Jan 1, 2012
23.51 %
Jan 1, 2013
23.51 %
Jan 1, 2014
10.33 %
Jan 1, 2015
23.51 %
Jan 1, 2016
8.94 %
Jan 1, 2017
23.51 %
Jan 1, 2018
6.2 %
Jan 1, 2019
4.04 %
Jan 1, 2020
23.51 %
Jan 1, 2021
39.36 %
Price targets and forecasts for Jointown Pharmaceutical Group Co are not yet available.

EESG©

Eulerpool ESG Scorecard© for the Jointown Pharmaceutical Group Co stock

74/100
99
Environment
86
Social
36
Governance
E

Environment

20
Scope 1 - Direct Emissions36,924.21
Scope 2 - Indirect emissions from purchased energy11,005.2
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions47,929.41
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees46.81
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Jointown Pharmaceutical Group Co shareholder structure

% Name
21.70237%
Shanghai Hongkang Industrial Investment Co., Ltd.
Shanghai Hongkang Industrial Investment Co., Ltd.
11.47758%
Shilong International Group (Hong Kong) Ltd.
Shilong International Group (Hong Kong) Ltd.
7.22914%
Chuchang Investment Group Co., Ltd.
Chuchang Investment Group Co., Ltd.
6.68737%
Zhongshan Guangyin Investment Ltd
Zhongshan Guangyin Investment Ltd
5.51432%
Beijing Dianjin Investment Co., Ltd.
Beijing Dianjin Investment Co., Ltd.
5.0276%
China Cinda Asset Management Co., Ltd.
China Cinda Asset Management Co., Ltd.
1.41254%
China Merchants Fund Management Co. Ltd.
China Merchants Fund Management Co. Ltd.
1.41218%
Liu (Shu Lin)
Liu (Shu Lin)
1.3654%
Great Wall Guotai (Zhoushan) Industrial M & A Restructuring Fund Partner
Great Wall Guotai (Zhoushan) Industrial M & A Restructuring Fund Partner
1.2049%
Liu (Zhao Nian)
Liu (Zhao Nian)
...

Jointown Pharmaceutical Group Co Executives and Management Board

WC

Mr. Weijun Chen

(46)

Deputy General Manager

Compensation2.71 M CNY
NY

Mr. Nie Yang

(43)

Deputy General Manager

Compensation1.94 M CNY
QW

Mr. Qibing Wang

(60)

Deputy General Manager

Compensation1.58 M CNY
DL

Mr. Dengpan Liu

(50)

Vice Chairman of the Board · since 2008

Compensation1.56 M CNY
ZX

Mr. Zhijun Xu

(48)

Deputy General Manager

Compensation1.42 M CNY

Jointown Pharmaceutical Group Co Supply Chain

Frequently asked questions about Jointown Pharmaceutical Group Co

The business model of Jointown Pharmaceutical Group Co Ltd, a leading pharmaceutical company, focuses on the comprehensive distribution of pharmaceutical and healthcare products. Jointown operates a vast network of distribution centers and retail pharmacies, enabling it to effectively manage the procurement, warehousing, logistics, and sales of medicines and medical supplies. By leveraging its extensive industry experience and strong relationships with suppliers, Jointown ensures efficient supply chain management and timely delivery of products to hospitals, clinics, and individuals. This business model allows Jointown to contribute to the healthcare industry by providing quality medicines and healthcare solutions to patients across China and beyond.

All fundamentals and in-depth analysis of Jointown Pharmaceutical Group Co

Our stock analysis for Jointown Pharmaceutical Group Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Jointown Pharmaceutical Group Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Jointown Pharmaceutical Group Co Stock
Jointown Pharmaceutical Group Co Revenue→
Jointown Pharmaceutical Group Co Stock
Jointown Pharmaceutical Group Co Net Income→
Jointown Pharmaceutical Group Co Stock
Jointown Pharmaceutical Group Co P/E→
Jointown Pharmaceutical Group Co Stock
Jointown Pharmaceutical Group Co P/S→
Jointown Pharmaceutical Group Co Stock
Jointown Pharmaceutical Group Co EBIT→
Jointown Pharmaceutical Group Co Stock
Jointown Pharmaceutical Group Co Dividend→
Jointown Pharmaceutical Group Co Stock
Jointown Pharmaceutical Group Co Directors Dealings→
Jointown Pharmaceutical Group Co Stock
Jointown Pharmaceutical Group Co Stocks→
Jointown Pharmaceutical Group Co Stock
Jointown Pharmaceutical Group Co Market capitalization→
Jointown Pharmaceutical Group Co Stock
Jointown Pharmaceutical Group Co Debt→
Jointown Pharmaceutical Group Co Stock
Jointown Pharmaceutical Group Co Liabilities→
Jointown Pharmaceutical Group Co Stock
Jointown Pharmaceutical Group Co Equity→
Jointown Pharmaceutical Group Co Stock
Jointown Pharmaceutical Group Co AAQS→
Jointown Pharmaceutical Group Co Stock
Jointown Pharmaceutical Group Co Employees→
Jointown Pharmaceutical Group Co Stock
Jointown Pharmaceutical Group Co ROE→
Jointown Pharmaceutical Group Co Stock
Jointown Pharmaceutical Group Co ROA→
Jointown Pharmaceutical Group Co Stock
Jointown Pharmaceutical Group Co ROCE→